How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million from $19.22 million last year. The company continues to progress in its AI-driven drug discovery efforts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results